Kintara Therapeutics, Inc. (KTRA)

USD 0.22

(-6.31%)

Market Cap (In USD)

11.98 Million

Revenue (In USD)

-

Net Income (In USD)

-8.5 Million

Avg. Volume

2.84 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.2049-26.214998
PE
-
EPS
-
Beta Value
0.812
ISIN
US49720K2006
CUSIP
49720K101
CIK
1498382
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Jeffrey A. Bacha B.Sc., M.B.A.
Employee Count
-
Website
https://www.kintara.com
Ipo Date
2013-02-22
Details
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.